ES2127409T3 - Metodo para la modulacion de la respuesta sexual en el hombre. - Google Patents
Metodo para la modulacion de la respuesta sexual en el hombre.Info
- Publication number
- ES2127409T3 ES2127409T3 ES94925240T ES94925240T ES2127409T3 ES 2127409 T3 ES2127409 T3 ES 2127409T3 ES 94925240 T ES94925240 T ES 94925240T ES 94925240 T ES94925240 T ES 94925240T ES 2127409 T3 ES2127409 T3 ES 2127409T3
- Authority
- ES
- Spain
- Prior art keywords
- men
- modulation
- sexual response
- response
- sexual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Percussion Or Vibration Massage (AREA)
- Control Of Fluid Pressure (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA INVENCION SE DIRIGE A METODOS MEJORADOS PARA MODULAR LA RESPUESTA SEXUAL HUMANA MEDIANTE LA ADMINISTRACION DE UN VASODILATADOR A LA CIRCULACION MEDIANTE UNA RUTA DE ADMINISTRACION QUE EVITE EL EFECTO DE "PRIMER PASO".
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10643493A | 1993-08-13 | 1993-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2127409T3 true ES2127409T3 (es) | 1999-04-16 |
Family
ID=22311403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94925240T Expired - Lifetime ES2127409T3 (es) | 1993-08-13 | 1994-08-10 | Metodo para la modulacion de la respuesta sexual en el hombre. |
Country Status (16)
Country | Link |
---|---|
US (1) | US5565466A (es) |
EP (1) | EP0714300B1 (es) |
JP (1) | JP3782101B2 (es) |
KR (1) | KR100391025B1 (es) |
CN (1) | CN1103589C (es) |
AT (1) | ATE174795T1 (es) |
BR (1) | BR9407250A (es) |
CA (1) | CA2169071C (es) |
DE (1) | DE69415535T2 (es) |
DK (1) | DK0714300T3 (es) |
ES (1) | ES2127409T3 (es) |
GR (1) | GR3029500T3 (es) |
NO (1) | NO311785B1 (es) |
NZ (1) | NZ271567A (es) |
WO (1) | WO1995005172A1 (es) |
ZA (1) | ZA946123B (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
US6007836A (en) * | 1993-05-28 | 1999-12-28 | Vericade, Inc. | Transdermal vasodilator |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
US6387407B1 (en) | 1995-09-29 | 2002-05-14 | L.A.M. Pharmaceutical Corporation | Topical drug preparations |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6323211B1 (en) | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
FR2748658B1 (fr) * | 1996-05-15 | 2000-08-18 | Biotec Centre Sa | Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique |
JP2000516117A (ja) * | 1996-08-09 | 2000-12-05 | ウロメトリックス・インコーポレイテッド | 男性不能症診断超音波システム |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
USRE37234E1 (en) * | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
DE19646392A1 (de) | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
EP0996447B1 (en) * | 1997-05-19 | 2006-07-19 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
DE69833254T2 (de) * | 1997-06-23 | 2006-11-02 | Cellegy Pharmaceuticals, Inc., Brisbane | Microdosistherapie von gefässbedingten erscheinungen durch no-donoren |
EP1535611A3 (en) * | 1997-06-23 | 2009-09-16 | Strakan International Limited | Microdose therapy of vascular conditions by no donors |
FR2765483B1 (fr) * | 1997-07-04 | 2000-02-04 | Philippe Gorny | Medicament destine a traiter les dysfonctions erectiles |
AU742787B2 (en) | 1997-07-09 | 2002-01-10 | Androsolutions, Inc. | Improved methods and compositions for treating male erectile dysfunction |
US6103765A (en) | 1997-07-09 | 2000-08-15 | Androsolutions, Inc. | Methods for treating male erectile dysfunction |
US6251076B1 (en) | 1997-08-01 | 2001-06-26 | Urometrics Inc. | Male impotence diagnostic ultrasound system |
US5947901A (en) | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
US5879665A (en) * | 1997-09-25 | 1999-03-09 | The Board Of Regents Of The University Of Oklahoma | Composition for causing skin lightening |
US5919436A (en) * | 1997-09-25 | 1999-07-06 | The Board Of Regents Of The University Of Oklahoma | Method of lightening skin |
US6110448A (en) * | 1997-09-25 | 2000-08-29 | The Board Of Regents Of The University Of Oklahoma | Method for causing skin lightening |
GB9720797D0 (en) * | 1997-09-30 | 1997-12-03 | Rhodes John | Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome |
US6593369B2 (en) | 1997-10-20 | 2003-07-15 | Vivus, Inc. | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US5877216A (en) * | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
WO1999021562A1 (en) | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
US20050070516A1 (en) * | 1997-10-28 | 2005-03-31 | Vivus Inc. | As-needed administration of an androgenic agent to enhance female desire and responsiveness |
US20040044080A1 (en) * | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
AUPP010397A0 (en) * | 1997-10-30 | 1997-11-20 | Vaisman, Jakov | Method and composition for treatment of sexual dysfunction |
US6472425B1 (en) * | 1997-10-31 | 2002-10-29 | Nitromed, Inc. | Methods for treating female sexual dysfunctions |
CA2318081A1 (en) | 1998-01-13 | 1999-07-22 | Urometrics, Inc. | Devices and methods for monitoring female arousal |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
GB9802078D0 (en) * | 1998-01-30 | 1998-03-25 | Futura Medical Limited | Preparation for treatment of erectile dysfunction |
FR2774594A1 (fr) * | 1998-02-12 | 1999-08-13 | Philippe Gorny | Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles |
FR2774593B1 (fr) * | 1998-02-12 | 2000-05-05 | Philippe Gorny | Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines |
US6124461A (en) * | 1998-05-26 | 2000-09-26 | Saint Louis University, Health Services Center, Research Administration | Compounds, compositions, and methods for treating erectile dysfunction |
US6365590B1 (en) | 1998-05-26 | 2002-04-02 | Saint Louis University | Compounds, compositions and methods for treating erectile dysfunction |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
TWI223598B (en) * | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
WO2000012110A2 (en) * | 1998-08-26 | 2000-03-09 | Queen's University At Kingston | Use of anti(w)pressor agents for vascular remodeling in genital dysfunction |
US6482426B1 (en) | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
MXPA01010021A (es) * | 1999-04-06 | 2002-07-30 | Zonagen Inc | Metodos para la modulacion de la respuesta sexual humana.. |
US6214849B1 (en) | 1999-04-29 | 2001-04-10 | Lupin Laboratories Limited | Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans |
IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
US6405219B2 (en) | 1999-06-22 | 2002-06-11 | F5 Networks, Inc. | Method and system for automatically updating the version of a set of files stored on content servers |
US6730691B1 (en) | 2000-02-10 | 2004-05-04 | Miles A. Galin | Uses of alpha adrenergic blocking agents |
CA2408399A1 (en) | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
US20040137081A1 (en) * | 2003-01-13 | 2004-07-15 | Peter Rohdewald | Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins |
EP1328281B1 (en) * | 2000-06-27 | 2007-08-15 | Qualilife Pharmaceuticals Inc. | Compositions and methods for treating females sexual response |
FI20002755A0 (fi) * | 2000-12-15 | 2000-12-15 | Orion Yhtymae Oyj | Menetelmä erektiilin dysfunktion hoitamiseen |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
EP1365740A1 (en) * | 2001-02-08 | 2003-12-03 | Pharmacia Corporation | Rapid-onset medicament for the treatment of sexual dysfunction |
US6987129B2 (en) | 2001-03-06 | 2006-01-17 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
US20020172712A1 (en) * | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
US20030138494A1 (en) * | 2001-05-15 | 2003-07-24 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
US20030158184A1 (en) * | 2001-12-21 | 2003-08-21 | Garvey David S. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
MXPA06013133A (es) | 2004-05-11 | 2007-05-23 | Emotional Brain Bv | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2010040555A2 (en) * | 2008-10-10 | 2010-04-15 | Milux Holding Sa | Stimulation of penis erection |
US8939889B1 (en) | 2013-08-22 | 2015-01-27 | Coloplast A/S | Pump bulb for an implantable penile prosthetic |
WO2016081517A2 (en) * | 2014-11-17 | 2016-05-26 | Borkholder David A | Pulse wave velocity, arterial compliance, and blood pressure |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3943246A (en) * | 1972-07-10 | 1976-03-09 | Sandoz Ltd. | Organic compounds |
US4139617A (en) * | 1974-05-13 | 1979-02-13 | Richardson-Merrell Inc. | 19-Oxygenated-androst-5-enes for the enhancement of libido |
US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
US4530920A (en) * | 1983-11-07 | 1985-07-23 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist |
US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
US4863911A (en) * | 1986-08-04 | 1989-09-05 | University Of Florida | Method for treating male sexual dysfunction |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
US5059603A (en) * | 1989-06-12 | 1991-10-22 | Centuries Laboratories, Inc. | Method and composition for treating impotence |
US5065744A (en) * | 1989-06-16 | 1991-11-19 | Zusmanovsky Zinovy A | Device for treatment of sexual impotence in human males |
FR2649613B1 (fr) * | 1989-07-11 | 1991-09-27 | Virag Ronald | Medicament vaso-actif |
US5236904A (en) * | 1989-09-18 | 1993-08-17 | Senetek, Plc | Erection-inducing methods and compositions |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
-
1994
- 1994-08-09 US US08/286,615 patent/US5565466A/en not_active Expired - Lifetime
- 1994-08-10 DE DE69415535T patent/DE69415535T2/de not_active Expired - Fee Related
- 1994-08-10 KR KR1019960700714A patent/KR100391025B1/ko active IP Right Grant
- 1994-08-10 AT AT94925240T patent/ATE174795T1/de not_active IP Right Cessation
- 1994-08-10 EP EP94925240A patent/EP0714300B1/en not_active Expired - Lifetime
- 1994-08-10 NZ NZ271567A patent/NZ271567A/en not_active IP Right Cessation
- 1994-08-10 WO PCT/US1994/009048 patent/WO1995005172A1/en active IP Right Grant
- 1994-08-10 BR BR9407250A patent/BR9407250A/pt not_active Application Discontinuation
- 1994-08-10 DK DK94925240T patent/DK0714300T3/da active
- 1994-08-10 CN CN94193071A patent/CN1103589C/zh not_active Expired - Fee Related
- 1994-08-10 ES ES94925240T patent/ES2127409T3/es not_active Expired - Lifetime
- 1994-08-10 CA CA002169071A patent/CA2169071C/en not_active Expired - Lifetime
- 1994-08-10 JP JP50706195A patent/JP3782101B2/ja not_active Expired - Lifetime
- 1994-08-15 ZA ZA946123A patent/ZA946123B/xx unknown
-
1996
- 1996-02-12 NO NO19960549A patent/NO311785B1/no not_active IP Right Cessation
-
1999
- 1999-02-26 GR GR990400597T patent/GR3029500T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
BR9407250A (pt) | 1996-09-24 |
DE69415535T2 (de) | 1999-06-17 |
NO960549L (no) | 1996-04-12 |
WO1995005172A1 (en) | 1995-02-23 |
CN1103589C (zh) | 2003-03-26 |
CN1128950A (zh) | 1996-08-14 |
JP3782101B2 (ja) | 2006-06-07 |
EP0714300A4 (en) | 1996-07-24 |
AU7523894A (en) | 1995-03-14 |
DK0714300T3 (da) | 1999-08-23 |
EP0714300B1 (en) | 1998-12-23 |
DE69415535D1 (de) | 1999-02-04 |
NO960549D0 (no) | 1996-02-12 |
CA2169071A1 (en) | 1995-02-23 |
ZA946123B (en) | 1995-03-20 |
NO311785B1 (no) | 2002-01-28 |
ATE174795T1 (de) | 1999-01-15 |
GR3029500T3 (en) | 1999-05-28 |
KR100391025B1 (ko) | 2003-10-04 |
KR960703588A (ko) | 1996-08-31 |
CA2169071C (en) | 2008-10-21 |
NZ271567A (en) | 1997-12-19 |
AU696815B2 (en) | 1998-09-17 |
US5565466A (en) | 1996-10-15 |
EP0714300A1 (en) | 1996-06-05 |
JPH09501677A (ja) | 1997-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2127409T3 (es) | Metodo para la modulacion de la respuesta sexual en el hombre. | |
EE03472B1 (et) | Ravimvormid inimese seksuaalreaktsiooni moduleerimiseks | |
BR9712491A (pt) | Composições cosméticas | |
SE8501709D0 (sv) | Improvements in or relating to intrleukin therapy | |
ATE210127T1 (de) | 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung | |
ES2196024T3 (es) | Vacunas conjugadas de gangliosido-klh con qs-21. | |
ES2194107T3 (es) | Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales. | |
DE69325256D1 (de) | Insizierbare lecithin gel | |
ATE211467T1 (de) | 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung | |
ES2170335T3 (es) | Estabilizacion de un retinoide inestable en emulsiones aceite en agua para composiciones para el cuidado de la piel. | |
ES2173284T3 (es) | Agentes endoparasicitidas. | |
NZ314839A (en) | 1,25-Dihydroxy-16,23Z-diene-20-epi-16-ene-cholecalciferol (Vitamin D3) analogues | |
PT998287E (pt) | Utilizacao de levobupivacaina | |
ES2168766T3 (es) | Preparacion farmaceutica que incluye el propeptido vwf. | |
ES2058191T3 (es) | Acidos 2-fenil-4-quinolincarboxilicos substituidos. | |
SE503436C2 (sv) | Pyroglutamidderivat | |
YU49138B (sh) | Proteinski derivat humane lipaze stimulisane žučnom soli | |
ES2159054T3 (es) | Compuestos di-terc-butil-fenolicos que contienen azufre utiles como agentes antiinflamatorios. | |
ES2195158T3 (es) | Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas. | |
ES2084348T3 (es) | N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares. | |
DE69729201T2 (de) | Sulfonfluoride zur behandlung von der alzheimerischen krankheit | |
ES2145216T3 (es) | Procedimiento de redistribucion de policarbonatos. | |
ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. | |
ES2160969T3 (es) | Derivados anticonvulsivos utiles en el tratamiento de la psoriasis. | |
NO995132L (no) | Fremgangsmåte for reduksjon av fibrinogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 714300 Country of ref document: ES |